All reports
Pharmaceutical
Biosimilars & Generics
Pharma M&A and China Licensing Deals: Pipeline and Outlook
Code: NSC/PHRM/0020Published May 07, 2026Data window: 3 months
About this report
Boom in China biotech deals (Akeso, BeiGene, LianBio) and M&A strategies under IRA pressure.
Humans at the core of the analysis
Partner specialist firms, independent domain experts and our in-house analyst team: every report is written and reviewed by humans who cross-check signals, verify sources and prioritise what matters.
Key insights
Request the sample to discover the report's key insights.
Table of contents
The detailed table of contents is shared with the free sample.